Recent studies have shown that mutations in KRAS, SKT11, KEAP1, JAK1/2, B2M, APC, MTOR, and TP53 and co-mutations of these genes are the main determinants of mechanisms of resistance to ICIs in NSCLC patients. Here, KRAS is linked to non-small cell lung carcinoma.